EFFECTS OF TAMOXIFEN ON THE FEMALE GENITAL TRACT

MARIO PULJIZ, DAMIR DANOLIĆ, ILIJA ALVIR and IVICA MAMIĆ

Department of Gynecologic Oncology, University Hospital for Tumors, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia

Summary

Tamoxifen, a triphenylethyleneestrogen receptor modulator, is an effective treatment for estrogen receptor positive breast cancer patients. It acts as an estrogen antagonist in breast tissue and a week estrogen agonist in the female genital tract. Its estrogen agonist properties reflect on increased risk of gynaecologic pathologies and includes the development of endometrial cancer, endometrial hyperplasia, endometrial polyps, adenomyosis, leiomyomas, uterine sarcomas, cervical polyps and ovarian cysts. Breast cancer patients during tamoxifen treatment should be under close gynaecological and ultrasonographic surveillance.

KEY WORDS: tamoxifen, breast cancer, female genital tract, endometrial cancer

INTRODUCTION

Tamoxifen, a triphenylethyleneestrogen receptor modulator, is an effective treatment for estrogen receptor (ER) positive breast cancer patients. It has been conclusively demonstrated to reduce the risk of breast cancer recurrence in women with ER positive breast cancer by binding to ERs and blocking tumor proliferation (1). Tamoxifen treatment for 5 years reduces the rate of recurrence during the treatment and throughout the first decade after diagnosis and reduces breast cancer mortality rate by a third throughout the first 15 years after diagnosis (2). Prophylactic use of tamoxifen reduces the incidence of ER-positive breast cancer in healthy women for 45 % (3). The side effects of tamoxifen are diverse and related to its mechanism of action, with mixed agonistic/antagonistic effects on various tissues. Its oestrogen-agonist properties reflects on increased risk of gynaecologic pathologies and includes the development of endometrial cancer, endometrial hyperplasia, endometrial polyps, adenomyosis, leiomyomas, uterine sarcomas, cervical polyps and ovarian cysts (3,4).

Tamoxifen is listed as human carcinogen since 1996.
GYNAECOLOGICAL CHANGES IN PREMENOPAUSAL BREAST CANCER PATIENTS RECEIVING TAMOXIFEN

The tamoxifen effects on female genital tract varies with the serum estradiol (E2) concentration and hence menopausal status of the patient (5,6). Clinical data indicate that tamoxifen therapy do not increased risk of endometrial pathology in premenopausal patients (3). Premenopausal women with continued ovarian activity and therefore elevated serum E2 levels have a little, or no risk of tamoxifen causing uterine cancer (2,3). In prospective study Cheng et al. detected no differences in mean endometrial thickness and histopathologic findings in premenopausal symptomatic patients, regardless of tamoxifen ingestion and concluded that tamoxifen might be associated with premalignant or malignant changes of endometrium only in symptomatic postmenopausal women (7). In their study, in premenopausal women using tamoxifen endometrial thickness was not increased. Chang et al. reported that patients who became amenorrheic during long-term tamoxifen treatment with low serum E2 levels have increased endometrial thickness on ultrasound, increased frequency of endometrial pathology and may be at special risk of endometrial cancer (8). Tamoxifen, in amenorrheic women with low serum E2 levels, causes endometrial thickening and in women with elevated serum E2 levels has an opposite antiestrogenic effect (8). Chen et al. in their retrospective cohort study including 74,280 tamoxifen treated breast cancer patients concluded that tamoxifen use for more than three years and/or patients older than 35 years have significantly increased risk for developing endometrial cancer (9). This study obtained several unique findings that are not in accordance with previous studies. Increased endometrial cancer risk was usually reported after 5-year tamoxifen use (10,11) and in accordance with menopausal status as mentioned above (2,7,9). Patient age (>35 years) became an important risk factor for the development of endometrial cancer in tamoxifen treated breast cancer patients.

Formation of ovarian cysts in breast cancer patients during tamoxifen treatment has also been reported (3,12). Mourits et al. in cross-sectional study reported that ovarian cysts in tamoxifen treated breast cancer patients develop only if ova-

GYNAECOLOGICAL CHANGES IN POSTMENOPAUSAL BREAST CANCER PATIENTS RECEIVING TAMOXIFEN

The increased risk of endometrial cancer and benign uterine alterations has been reported for postmenopausal women associated with long term tamoxifen treatment (3,9,15). Tamoxifen is an estrogen agonist in the female genital tract in postmenopausal women. Deligdisch et al. evaluated endometrial histopathologic findings from 700 breast cancer patients treated with tamoxifen and found endometrial polyps, hyperplasia and cancer in one-third of all patients (16). These side effects are related to tamoxifen ability to stimulate proliferation of endometrium (4). Endometrial polyps occur in 8-50% of breast cancer patients treated with tamoxifen (3,16-18). Such polyps differ histologically from endometrial polyps of healthy patients not receiving tamoxifen and have more often (10-20 fold) malignant changes (3). Deligdisch et al. found 15 of 33 endometrial cancers in endometrial polyps (16). Endometrial hyperplasia occurs in 16-50% of breast cancer patients treated with tamoxifen (3,16-18). If endometrial atypical hyperplasia or endometrial complex hyperplasia without atypia is present cessation of tamoxifen therapy is advisable and if not, hysterectomy may be an option (3). Tamoxifen use increases the risk of endometrial cancer by 2 to 4 fold with overall incidence of 1.6-3.0 per 1000 tamoxifen treated breast cancer patients (2,3,19).
Van Leeuwen et al (20) reported that women who had used tamoxifen for more than 2 years had greater risk of endometrial cancer than never users. There was a significant trend of increasing risk of endometrial cancer with duration of tamoxifen use and also with cumulative dose (20). There is no difference in histologic phenotypes or prognostic factors of endometrial cancers found in tamoxifen treated patients from those of patients not receiving tamoxifen. In breast cancer patient with planned tamoxifen therapy pre-treatment-transvaginal ultrasonography screening is recommended to reveal high-risk group of patients with endometrial thickening. Transvaginal ultrasonography is also used to triage tamoxifen treated breast cancer patients. Standard, accepted endometrial thickness cut-off point is 5 mm in postmenopausal women, but with low frequency of significant findings on hysteroscopy. Love et al. recommended endometrial thickness cut-off point of 8 mm in asymptomatic tamoxifen treated breast cancer patients (21). Seoud et al. found that all patients with an abnormal endometrium had abnormal vaginal bleeding with no correlation between endometrial thickness and endometrial pathology and concluded that the value of routine ultrasonography screening for endometrial pathology is controversial (22). Endometrial sampling should always be obtained in symptomatic patients.

In addition, tamoxifen treatment is significantly associated with appearance of uterine sarcoma (especially MMMTs), endometrial stromal sarcomas, adenofibromas, cervical polyps, development of endometriosis and with growth of leiomyomas in postmenopausal breast cancer patients (3). The relationship between tamoxifen use and cervical cancer and vaginal neoplasms has not been reported in literature (3). There is no consensus whether postmenopausal breast cancer tamoxifen users risk developing ovarian cancer. Regardless of tamoxifen treatment, these patients have increased risk to develop ovarian tumors due to genetic factors (23).

The benefits of tamoxifen therapy are still without debate, despite possible severe side effects of this drug.

CONCLUSION

Breast cancer patients during tamoxifen treatment should be under close gynecological and ultrasonographic surveillance. It is recommended that all tamoxifen treated breast cancer patients (premenopausal and postmenopausal) should undergo gynaecological and transvaginal ultrasonographic examination every 4-6 months or at least annually. Endometrial sampling should be obtained when the endometrium is thickened or in the event of abnormal uterine bleeding or vaginal discharge.

REFERENCES


Author’s address: Mario Puljiz, Department of Gynecologic Oncology, University Hospital for Tumors, University Hospital Center Sestre milosrdnice, Ilica 197, 10000 Zagreb, Croatia; e-mail: mario.puljiz@kbsm.hr